ATM-3507

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

ATM-3507 

ATM-3507 是原肌球蛋白 (tropomyosin) 的一个有效抑制剂,其在人类黑色素瘤细胞系中的 IC50 值约为 3.83-6.84 μM。

ATM-3507

ATM-3507 Chemical Structure

CAS No. : 1861449-70-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

ATM-3507 的其他形式现货产品:

ATM-3507 trihydrochloride

生物活性

ATM-3507 is a potent tropomyosin inhibitor with IC50s from 3.83-6.84 μM in human melanoma cell lines.

IC50 & Target

IC50: 3.83-6.84 μM (tropomyosin, in human melanoma celllines)[1].

体外研究
(In Vitro)

The cell lines differ in their relative expression of Tpm3.1 as well as in the expression of other isoforms. After determing the IC50 concentrations for TR100 and ATM-3507 (CHLA-20: 4.99±0.45 μM, CHP-134: 3.83±0.67 μM, CHLA-90: 6.84±2.37 μM, SK-N-BE(2): 5.00±0.42 μM) in each of the neuroblastoma cell lines, combinations of tropomyosin inhibitors plus Vincristine are tested at levels of each drug alone that kill less than 50% of the neuroblastoma cells. The combinations of both tropomyosin inhibitors plus Vincristine are completely cytotoxic in CHLA-20 cells. All 4 cell lines show some degree of synergy as determined by the Chou–Talalay method. The effect is not limited to the vinca alkaloids as a similar combination efficacy using paclitaxel plus TR100 or ATM-3507[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The maximal tolerance dose (MTD) for TR100 and ATM-3507 is 60 and 150 mg/kg, respectively. It is found that a significant inhibition of tumor growth and prolongation of animal survival using either combination compared with each monotherapy. The median survival of mice increased from 18 days for mice treated with ATM-3507 to more than 49 days for mice treated with the combination. It is also found that twice weekly intravenous administration of ATM-3507 also show combination efficacy. The impact of each treatment or the combination on body weight is minimal. Drug levels are measured following the intravenous administration of ATM-3507 at 30 mg/kg in Balb/c mice (n=3 per time point). The mean half-life of ATM-3507 is 5.01 hrs for the terminal elimination phase. The mean AUC0-t in the plasma is 14,548 ng/h/mL. The Cmax of ATM-3507 is 5,758 ng/mL and the the t1/2 is 5.01 h. The observed plasma clearance and volume of distribution at steady state of ATM-3507 is 33.8 mL/min/kg and 7.23 L/kg, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

611.79

Formula

C37H46FN5O2

CAS 号

1861449-70-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Currier MA, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.Mol Cancer Ther. 2017 Aug;16(8):1555-1565.

Cell Assay
[1]

The 4 melanoma cell lines CHLA-20, CHLA-90, SK-N-BE(2) and CHP-134 are cultured at 37°C in a humidified incubator at 5% CO2 and supplemented 100 U/mL penicillin and 100 mg/mL streptomycin. Cells are plated in 96-well plates at 2000-4000 cells per well, incubated at 37°C overnight and then treated with various concentrations of TR100/ATM-3507 (0.1-2.5 μM) alone, TR100 and ATM-3507 plus various chemotherapy drugs. The cell viability is performed on day 3-5. For the dosing schedule optimization experiment, TR100 or Vincristine is added at day 1 with the other being added at day 2 or both TR100 and Vincristine are added on day 1 and plates are read at day 5. Results are presented as percentage of survival cells compared with controls. All cell viability assays are run in quadruplicate and the data shown are representative of at least 2 independent experiments[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
Female athymic nude mice (age 4-6 weeks) are used. Mice are subcutaneously injected with 5.0×106 CHLA-20 cells in a 150 mL mix of PBS and Matrigel (2:1). ATM-3507 and TR100 are formulated at 15 mg/mL in 30% sulfobutyl-ether-b-cyclodextrin sodium salt (SBECD). Vincristine is dissolved in H2O at 0.125 mg/kg. When the tumors reached volumes of 200-400 mm3, mice are randomized into the study groups. Animals are followed until the animal reached endpoint criteria. Tumor size is measured using digital calipers twice per week and tumor volume is calculated. Mice are also weighed and observed twice per week for signs of endpoint condition. Mice that demonstrate signs of toxicity or reach endpoint criteria are humanely euthanized by CO2 as phyxiation and subjected to cervical dislocation as the secondary method of euthanasia[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Currier MA, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.Mol Cancer Ther. 2017 Aug;16(8):1555-1565.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务